BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China --(BUSINESS WIRE)-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun ina Phase I clinical study of BAT4306F in relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphomapatients. BAT4306F is an ADCC-enhanced CD20 monocl...
Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present one poster at the 2018 EORTC-NCI-AACR Symposium taking place November 13 - 16, 2018 in Dublin, Ireland. The poster, en...
Guangzhou, China -- Bio-Thera Solutions, announced the initiation of a Phase III clinical trial evaluating the efficacy and safety of its investigational HER2 Antibody-Drug Conjugate (ADC), BAT8001, in patients with HER-2 positive metastatic breast cancer who previously received trastuzumab separate...
